Kitahiroshima, Japan

Uiko Kagaya



Average Co-Inventor Count = 6.9

ph-index = 1


Location History:

  • Hokkaido, JP (2020)
  • Kitahiroshima, JP (2015 - 2022)

Company Filing History:


Years Active: 2015-2022

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Uiko Kagaya: Innovator in Medical Science

Introduction

Uiko Kagaya is a notable inventor based in Kitahiroshima, Japan. He has made significant contributions to the field of medical science, particularly in the development of vaccines and therapeutic agents. With a total of 3 patents, his work focuses on addressing critical health issues.

Latest Patents

One of Kagaya's latest patents is a malaria transmission-blocking vaccine. This invention aims to provide a vaccine using an immunogenic protein specifically expressed in the oocyst stage of malaria parasites. The vaccine is designed for oral administration and is capable of immunizing various animals involved in the malaria infectious cycle. Another significant patent is related to the therapeutic effect of oral interferon alpha administration on chronic intractable external otitis. This invention offers a composition that illustrates an immediate and sustained effect on this condition, providing a means for prevention and treatment.

Career Highlights

Throughout his career, Uiko Kagaya has worked with reputable organizations such as Hokusan Co. Ltd and the National Institute of Advanced Industrial Science and Technology. His experience in these institutions has contributed to his innovative research and development efforts.

Collaborations

Kagaya has collaborated with notable individuals in his field, including Noriko Tabayashi and Takeshi Matsumura. These partnerships have likely enhanced his research capabilities and broadened the impact of his inventions.

Conclusion

Uiko Kagaya's contributions to medical science through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in health solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…